id,trialid,source_register,date_registration,date_enrollement,retrospective_registration,normed_spon_names,recruitment_status,phase,study_type,countries,public_title,study_category,intervention,intervention_list,target_enrollment,web_address,trial_status,pcd_auto,scd_auto,rcd_auto,tabular_results,potential_other_results,registry_scraped,is_clinical_trial_manual,is_covid_manual,rcd_manual,pcd_manual,scd_manual,comments,is_intervention,is_reg_2020,is_not_withdrawn,is_eligible_study,is_rcd_cutoff_1,has_auto_reg_results_cutoff_1,is_searched_cutoff_1,is_not_withdrawn_manual,is_rcd_cutoff_1_manual,is_analysis_pop_cutoff_1,is_dupe,dupe_primary,trn_1,trn_2,trn_3,registry_1,registry_2,registry_3,pub_type_1,doi_1,pmid_1,cord_id_1,url_1,date_publication_1,date_completion_1,comments_results_1,pub_type_2,doi_2,pmid_2,cord_id_2,url_2,date_publication_2,date_completion_2,comments_results_2,pub_type_3,doi_3,pmid_3,cord_id_3,url_3,date_publication_3,date_completion_3,comments_results_3,pub_type_4,doi_4,pmid_4,cord_id_4,url_4,date_publication_4,date_completion_4,comments_results_4,pub_type_5,doi_5,pmid_5,cord_id_5,url_5,date_publication_5,date_completion_5,comments_results_5
tri00002,NCT04252885,ClinicalTrials.gov,2020-01-30,2020-01-28,TRUE,Guangzhou 8th People's Hospital,Recruiting,Phase 4,Interventional,China,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Drug,Lopinavir/ritonavir vs. umifenovir,Lopinavir/ritonavir; Umifenovir,125,https://clinicaltrials.gov/show/NCT04252885,Completed,2020-04-30,2020-05-31,2020-04-30,0,0,TRUE,TRUE,TRUE,2020-05-31,2020-04-30,2020-05-31,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04252885,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.1101/2020.03.19.20038984,NA,9hknw4ws,https://doi.org/10.1101/2020.03.19.20038984,2020-04-15,NA,NA,full_results_journal_article,10.1016/j.medj.2020.04.001,NA,ytqjxzaa,https://doi.org/10.1016/j.medj.2020.04.001; https://www.sciencedirect.com/science/article/pii/S2666634020300015?v=s5; https://api.elsevier.com/content/article/pii/S2666634020300015,2020-05-04,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00022,ChiCTR2000029853,ChiCTR,2020-02-15,2020-02-16,FALSE,People's Hospital of Guangshan County,Recruiting,Not Applicable,Interventional,China,"A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)",Drug,Azvudine,Azvudine,20,http://www.chictr.org.cn/showproj.aspx?proj=49532,Recruiting,NA,2020-04-16,2020-04-16,0,0,TRUE,TRUE,TRUE,2020-04-16,NA,2020-04-16,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000029853,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1002/advs.202001435,32837847,NA,https://onlinelibrary.wiley.com/doi/10.1002/advs.202001435,2020-07-14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00026,ChiCTR2000029822,ChiCTR,2020-02-14,2020-02-07,TRUE,Nanjing Second Hospital,Recruiting,Not Applicable,Interventional,No Country Given,A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,110,http://www.chictr.org.cn/showproj.aspx?proj=49502,Recruiting,NA,2020-04-30,2020-04-30,0,0,TRUE,TRUE,TRUE,2020-04-30,NA,2020-04-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000029822,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1038/s41421-020-00197-3,32802404,NA,NA,2020-08-05,NA,correspondence,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00042,ChiCTR2000029778,ChiCTR,2020-02-13,2020-02-14,FALSE,Shanghai University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,600,http://www.chictr.org.cn/showproj.aspx?proj=49422,Recruiting,NA,2020-05-13,2020-05-13,0,0,TRUE,FALSE,FALSE,2020-05-13,NA,2020-05-13,"Found results publication, but it's a retrospective study and should be excluded!",TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,NA,NA,ChiCTR2000029778,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1016/j.biopha.2020.110500,NA,NA,https://www.sciencedirect.com/science/article/pii/S0753332220306934?via%3Dihub,2020-07-04,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00047,ChiCTR2000029765,ChiCTR,2020-02-13,2020-02-10,TRUE,The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital),Recruiting,Phase 4,Interventional,China,"A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)",Drug,Tocilizumab,Tocilizumab,188,http://www.chictr.org.cn/showproj.aspx?proj=49409,Recruiting,NA,2020-05-10,2020-05-10,0,0,TRUE,TRUE,TRUE,2020-05-10,NA,2020-05-10,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000029765,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.2139/ssrn.3667681,NA,NA,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681,2020-08-29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00076,ChiCTR2000029600,ChiCTR,2020-02-06,2020-01-30,TRUE,The Third People's Hospital of Shenzhen,Recruiting,Not Applicable,Interventional,China,Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Favipiravir + interferon alpha vs. interferon alpha + Lopinavir/ritonavir + interferon alpha vs. interferon alpha,Favipiravir; interferon alpha; Lopinavir/ritonavir,90,http://www.chictr.org.cn/showproj.aspx?proj=49042,Recruiting,NA,2020-04-29,2020-04-29,0,0,TRUE,TRUE,TRUE,2020-04-29,NA,2020-04-29,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000029600,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1016/j.eng.2020.03.007,32346491,8caqxfxv,https://api.elsevier.com/content/article/pii/S2095809920300631; https://www.sciencedirect.com/science/article/pii/S2095809920300631; https://www.ncbi.nlm.nih.gov/pubmed/32346491/; https://doi.org/10.1,2020-03-18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00080,ChiCTR2000029559,ChiCTR,2020-02-04,2020-01-31,TRUE,Renmin Hospital of Wuhan University,Recruiting,Phase 4,Interventional,China,Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19),Drug,Hydroxychloroquine,Hydroxychloroquine,300,http://www.chictr.org.cn/showproj.aspx?proj=48880,Recruiting,NA,2020-02-29,2020-02-29,0,0,TRUE,TRUE,TRUE,2020-02-29,NA,2020-02-29,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000029559,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.03.22.20040758,NA,q8l3ra55,https://doi.org/10.1101/2020.03.22.20040758,2020-03-30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00083,ChiCTR2000029544,ChiCTR,2020-02-03,2020-02-04,FALSE,The First Affiliated Hospital of Zhejiang University School of Medicine,Not Recruiting,Not Applicable,Interventional,China,"A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy",Drug,Baloxavir + Marboxil vs. Favipiravir,Baloxavir; Marboxil; Favipiravir,30,http://www.chictr.org.cn/showproj.aspx?proj=49013,Not yet recruiting,NA,2020-05-31,2020-05-31,0,0,TRUE,TRUE,TRUE,2020-05-31,NA,2020-05-31,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000029544,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.04.29.20085761,NA,NA,https://www.medrxiv.org/content/10.1101/2020.04.29.20085761v1,2020-05-05,NA,NA,full_results_journal_article,10.1016/j.ejps.2020.105631,33115675,NA,https://www.sciencedirect.com/science/article/abs/pii/S092809872030419X?via%3Dihub,2020-10-25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00084,ChiCTR2000029542,ChiCTR,2020-02-03,2020-02-03,FALSE,Sun Yat sen Memorial Hospital of Sun Yat sen University,Recruiting,Phase 4,Interventional,China,Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,20,http://www.chictr.org.cn/showproj.aspx?proj=48968,Recruiting,NA,2020-07-30,2020-07-30,0,0,TRUE,TRUE,TRUE,2020-07-30,NA,2020-07-30,"Result identified as ""interim"" but unclear whether interim, preliminary, etc.",TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,ChiCTR2000029542,NA,NA,ChiCTR,NA,NA,interim_results_journal_article,10.1093/jmcb/mjaa014,32236562,NA,https://academic.oup.com/jmcb/article/12/4/322/5814655,2020-04-01,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00101,ChiCTR2000029435,ChiCTR,2020-02-01,2020-02-01,FALSE,Wuhan First Hospital,Not Recruiting,Not Applicable,Interventional,China,Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,120,http://www.chictr.org.cn/showproj.aspx?proj=48827,Not yet recruiting,NA,2020-03-31,2020-03-31,0,0,TRUE,TRUE,TRUE,2020-03-31,NA,2020-03-31,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000029435,NA,NA,ChiCTR,NA,NA,other,NA,NA,NA,http://www.chictr.org.cn/showproj.aspx?proj=48827,NA,NA,uploaded doc in chinese as registry results but seems to be protocol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00103,ChiCTR2000029431,ChiCTR,2020-02-01,2020-01-29,TRUE,Affiliated Zhongshan Hospital of Dalian University,Recruiting,Not Applicable,Interventional,China,Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,45,http://www.chictr.org.cn/showproj.aspx?proj=48907,Recruiting,NA,2021-12-31,2021-12-31,0,0,TRUE,TRUE,TRUE,2021-12-31,NA,2021-12-31,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,ChiCTR2000029431,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.04.07.20054767,NA,gzao2fo6,https://doi.org/10.1101/2020.04.07.20054767,2020-04-14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00105,ChiCTR2000029418,ChiCTR,2020-01-30,2020-02-03,FALSE,Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,42,http://www.chictr.org.cn/showproj.aspx?proj=48886,Recruiting,NA,2020-08-31,2020-08-31,0,0,TRUE,TRUE,TRUE,2020-08-31,NA,2020-08-31,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,ChiCTR2000029418,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.03.27.20044974,NA,4as055wh,http://medrxiv.org/cgi/content/short/2020.03.27.20044974v1?rss=1,2020-04-01,NA,NA,full_results_journal_article,10.3389/fmed.2020.00256,32574340,c2erqns2,https://doi.org/10.3389/fmed.2020.00256; https://www.ncbi.nlm.nih.gov/pubmed/32574340/,2020-05-27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00107,ChiCTR2000029381,ChiCTR,2020-01-27,2020-01-24,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Not Recruiting,Phase 4,Interventional,China,A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,400,http://www.chictr.org.cn/showproj.aspx?proj=48768,Completed,NA,2020-12-31,2020-12-31,0,0,TRUE,TRUE,TRUE,2020-12-31,NA,2020-12-31,registration disappeared,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,ChiCTR2000029381,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.3760/cma.j.cn121430-20200406-00386,32527346,NA,NA,2020-04-28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00137,ChiCTR2000030058,ChiCTR,2020-02-22,2020-03-10,FALSE,Renmin Hospital of Wuhan University,Not Recruiting,Phase 3,Interventional,China,"A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)",Drug,Leflunomide,Leflunomide,200,http://www.chictr.org.cn/showproj.aspx?proj=49831,Not yet recruiting,NA,2020-05-30,2020-05-30,0,0,TRUE,TRUE,TRUE,2020-05-30,NA,2020-05-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000030058,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1093/cid/ciaa1417,NA,NA,NA,2020-09-21,NA,NA,full_results_journal_article,10.1007/s12250-020-00258-7,NA,NA,NA,2020-07-21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00139,ChiCTR2000030054,ChiCTR,2020-02-22,2020-02-22,FALSE,Zhongshan Hospital Affiliated to Xiamen University,Not Recruiting,Not Applicable,Interventional,China,"A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)",Drug,Chloroquine + Hydroxychloroquine,Chloroquine; Hydroxychloroquine,100,http://www.chictr.org.cn/showproj.aspx?proj=49869,Not yet recruiting,NA,2020-05-21,2020-05-21,0,0,TRUE,TRUE,TRUE,2020-05-21,NA,2020-05-21,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000030054,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.06.19.20136093,NA,t1vom8f3,http://medrxiv.org/cgi/content/short/2020.06.19.20136093v1?rss=1,2020-06-22,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00140,ChiCTR2000030046,ChiCTR,2020-02-21,2020-02-07,TRUE,"The First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)",Recruiting,Not Applicable,Interventional,China,A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19),ATMP,Plasma,Plasma,10,http://www.chictr.org.cn/showproj.aspx?proj=49861,Recruiting,NA,2020-08-31,2020-08-31,0,0,TRUE,TRUE,TRUE,2020-04-07,NA,2020-04-07,investigators updated trial completion date to account for earlier end and results publication,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,NA,NA,ChiCTR2000030046,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1073/pnas.2004168117,32253318,rbgoabfk,https://www.ncbi.nlm.nih.gov/pubmed/32253318/; https://doi.org/10.1073/pnas.2004168117,2020-04-06,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00159,ChiCTR2000030007,ChiCTR,2020-02-19,2020-02-03,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19),Drug,G-CSF,G-CSF,200,http://www.chictr.org.cn/showproj.aspx?proj=49619,Not yet recruiting,NA,2020-04-10,2020-04-10,0,0,TRUE,TRUE,TRUE,2020-04-10,NA,2020-04-10,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000030007,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1001/jamainternmed.2020.5503,32910179,NA,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770680,2020-09-10,2020-04-10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00164,ChiCTR2000030001,ChiCTR,2020-02-19,2020-02-15,TRUE,Health commission of Heilongjiang province,Recruiting,Phase 3,Interventional,China,"The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial",Drug,Triazavirin,Triazavirin,240,http://www.chictr.org.cn/showproj.aspx?proj=49723,Recruiting,NA,2020-05-28,2020-05-28,0,0,TRUE,TRUE,TRUE,2020-05-28,NA,2020-05-28,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000030001,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1016/j.eng.2020.08.011,32923016,NA,https://www.sciencedirect.com/science/article/pii/S2095809920302411?via%3Dihub,2020-09-08,NA,NA,summary_results,NA,NA,NA,http://www.chictr.org.cn/showproj.aspx?proj=49723,2020-06-17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00171,ChiCTR2000029990,ChiCTR,2020-02-18,2020-01-30,TRUE,"Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences",Recruiting,Phase 1/Phase 2,Interventional,China,Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),120,http://www.chictr.org.cn/showproj.aspx?proj=49674,Recruiting,NA,2020-03-31,2020-03-31,0,0,TRUE,TRUE,TRUE,2020-03-31,NA,2020-03-31,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000029990,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.14336/ad.2020.0228,32257537,ghfrwccu,https://www.ncbi.nlm.nih.gov/pubmed/32257537/; https://doi.org/10.14336/ad.2020.0228,2020-03-13,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00185,ChiCTR2000029851,ChiCTR,2020-02-15,2020-02-19,FALSE,"Zhongshan Hospital, Fudan University",Recruiting,Phase 4,Interventional,China,"A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)",Supplement,Alpha lipoic acid,Alpha lipoic acid,68,http://www.chictr.org.cn/showproj.aspx?proj=49534,Recruiting,NA,2020-03-10,2020-03-10,0,0,TRUE,TRUE,TRUE,2020-03-10,NA,2020-03-10,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000029851,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.04.15.20066266,NA,mvsnybbo,http://medrxiv.org/cgi/content/short/2020.04.15.20066266v1?rss=1,2020-04-21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00193,NCT04275245,ClinicalTrials.gov,2020-02-06,2020-02-03,TRUE,Tang-Du Hospital,Recruiting,Phase 1/Phase 2,Interventional,China,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,Drug,Mepolizumab,Mepolizumab,20,https://clinicaltrials.gov/show/NCT04275245,Recruiting,2020-12-31,2020-12-31,2020-12-31,0,0,TRUE,TRUE,TRUE,2020-12-31,2020-12-31,2020-12-31,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,NCT04275245,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.1101/2020.03.21.20040691,NA,6g34qwer,https://doi.org/10.1101/2020.03.21.20040691,2020-03-24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00230,ChiCTR2000030261,ChiCTR,2020-02-26,2020-03-01,FALSE,Wuxi Fifth People's Hospital,Not Recruiting,Not Applicable,Interventional,China,A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),26,http://www.chictr.org.cn/showproj.aspx?proj=49963,Not yet recruiting,NA,2020-05-31,2020-05-31,0,0,TRUE,TRUE,TRUE,2020-05-31,NA,2020-05-31,Interestingly one preprint contains 6 subjects and the other 7. ResearchSquare preprint under review at Stem Cell Research & Therapy.,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000030261,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.2139/ssrn.3678558,NA,NA,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3678558,2020-10-12,2020-04-30,NA,full_results_preprint,10.21203/rs.3.rs-99753/v1,NA,NA,https://www.researchsquare.com/article/rs-99753/v1,2020-11-02,2020-04-30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00248,ChiCTR2000030022,ChiCTR,2020-02-20,2020-02-22,FALSE,The First Affiliated Hospital of Anhui Medical University,Not Recruiting,Phase 4,Interventional,China,"A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=49797,Not yet recruiting,NA,2020-05-22,2020-05-22,0,0,TRUE,TRUE,TRUE,2020-05-22,NA,2020-05-22,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000030022,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1097/JBR.0000000000000076,NA,NA,https://journals.lww.com/jbioxresearch/Abstract/9000/Clinical_efficacy_of_low_dose_emetine_for_patients.99938.aspx,2020-12-03,NA,report incorrect dates (2019),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00270,ChiCTR2000030627,ChiCTR,2020-03-08,2020-02-01,TRUE,The First Affiliated Hospital of Zhengzhou University,Recruiting,Not Applicable,Interventional,China,Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases,ATMP,Plasma,Plasma,30,http://www.chictr.org.cn/showproj.aspx?proj=50727,Recruiting,NA,2020-05-30,2020-05-30,0,0,TRUE,TRUE,TRUE,2020-05-30,NA,2020-05-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000030627,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.08.02.20166710,NA,NA,https://www.medrxiv.org/content/10.1101/2020.08.02.20166710v1,2020-08-04,NA,"Trial registration had control. Full results preprint does NOT have control, but same study.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00319,ChiCTR2000029757,ChiCTR,2020-02-12,2020-02-14,FALSE,China-Japan Friendship Hospital,Recruiting,Not Applicable,Interventional,China,Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial,ATMP,Plasma,Plasma,200,http://www.chictr.org.cn/showproj.aspx?proj=49081,Recruiting,NA,2021-02-05,2021-02-05,0,0,TRUE,TRUE,TRUE,2021-02-05,NA,2021-02-05,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,ChiCTR2000029757,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1001/jama.2020.10044,32492084,NA,NA,2020-06-03,2020-04-28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00324,ChiCTR2000029308,ChiCTR,2020-01-23,2020-01-10,TRUE,Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital),Recruiting,Not Applicable,Interventional,China,"A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)",Drug,Lopinavir/ritonavir,lopinavir/ritonavir,160,http://www.chictr.org.cn/showproj.aspx?proj=48684,Recruiting,NA,2021-01-10,2021-01-10,0,0,TRUE,TRUE,TRUE,2021-01-10,NA,2021-01-10,found full results journal article though study is far from completed,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,ChiCTR2000029308,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1056/NEJMoa2001282,32187464,NA,NA,2020-03-18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00440,ChiCTR2000030545,ChiCTR,2020-03-06,2020-02-04,TRUE,Hubei Hospital of Traditional Chinese Medicine,Recruiting,Phase 4,Interventional,China,"Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=50126,Recruiting,NA,2020-04-30,2020-04-30,0,0,TRUE,TRUE,TRUE,2020-04-30,NA,2020-04-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000030545,NA,NA,ChiCTR,NA,NA,other,NA,NA,NA,https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/czh-1187,NA,NA,"Abstract, no link to full pub. Available only in WHO database with link to an ""internal database"" so unclear whether it is public.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00458,ChiCTR2000030055,ChiCTR,2020-02-22,2020-02-10,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Recruiting,Phase 4,Prognosis,China,Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19),Drug,Dipyridamole,Dipyridamole,460,http://www.chictr.org.cn/showproj.aspx?proj=49864,NA,NA,NA,NA,NA,NA,NA,TRUE,TRUE,2020-04-10,NA,2020-04-10,NA,FALSE,TRUE,TRUE,FALSE,FALSE,NA,FALSE,TRUE,TRUE,FALSE,NA,NA,ChiCTR2000030055,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.02.27.20027557,NA,NA,https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1,2020-02-29,NA,NA,full_results_journal_article,10.1016/j.apsb.2020.04.008,32318327,k7bh8bf7,https://api.elsevier.com/content/article/pii/S2211383520305529; https://doi.org/10.1016/j.apsb.2020.04.008; https://www.ncbi.nlm.nih.gov/pubmed/32318327/; https://www.sciencedirect.com/science/article,2020-04-20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00507,ChiCTR2000030939,ChiCTR,2020-03-18,2020-03-16,TRUE,PLA General Hospital,Recruiting,Not Applicable,Interventional,China,Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia (COVID-19),ATMP,Gene-derived protein,Gene-derived protein,10,http://www.chictr.org.cn/showproj.aspx?proj=51059,Recruiting,NA,2020-10-01,2020-10-01,0,0,TRUE,TRUE,TRUE,2020-10-01,NA,2020-10-01,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,ChiCTR2000030939,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.05.11.20064584,NA,7g3keqx9,http://medrxiv.org/cgi/content/short/2020.05.11.20064584v1?rss=1,2020-05-15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00521,ChiCTR2000030254,ChiCTR,2020-02-26,2020-02-20,TRUE,Zhongnan Hospital of Wuhan University,Not Recruiting,Not Applicable,Interventional,China,"the Efficacy and Safety of Favipiravir for novel coronavirus–infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study",Drug,Favipiravir vs. Umifenovir,Favipiravir; Umifenovir,240,http://www.chictr.org.cn/showproj.aspx?proj=50137,Completed,NA,2020-03-20,2020-03-20,0,0,TRUE,TRUE,TRUE,2020-03-20,NA,2020-03-20,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000030254,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.03.17.20037432,NA,NA,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4,2020-03-20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00526,ChiCTR2000029868,ChiCTR,2020-02-15,2020-02-11,TRUE,"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine",Not Recruiting,Phase 4,Interventional,China,"Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial",Drug,Hydroxychloroquine,Hydroxychloroquine,360,http://www.chictr.org.cn/showproj.aspx?proj=49524,Completed,NA,2020-06-30,2020-06-30,0,0,TRUE,TRUE,TRUE,2020-06-30,NA,2020-06-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000029868,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1136/bmj.m1849,32409561,NA,NA,2020-05-14,2020-03-14,NA,full_results_preprint,10.1101/2020.04.10.20060558,NA,NA,https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v1?versioned=true,2020-04-14,2020-03-14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00530,ChiCTR2000029496,ChiCTR,2020-02-03,2020-01-29,TRUE,The First Hospital of Changsha; The Second Xiangya Hospital of Central South University,Recruiting,Phase 4,Interventional,China,"A randomized, open label, parallel controlled trial of evaluating the efficacy of recombinant cytokine gene-derived protein injection for clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)",ATMP,Gene-derived protein,Gene-derived protein,90,http://www.chictr.org.cn/showproj.aspx?proj=48809,Recruiting,NA,2021-01-29,2021-01-29,0,0,TRUE,TRUE,TRUE,2021-01-29,NA,2021-01-29,published before completion date,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,ChiCTR2000029496,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.04.24.20077735,NA,rq5gh710,http://medrxiv.org/cgi/content/short/2020.04.24.20077735v1?rss=1,2020-04-29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00531,EUCTR2020-000890-25-FR,EU Clinical Trials Register,2020-03-10,2020-03-05,TRUE,Fondation Méditerranée Infection (FMI) - IHU Méditerranée Infection,Authorised,Phase 3,Interventional,France,Hydroxychloroquine as a treatment for coronavirus disease COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,25,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000890-25,['Ongoing'],NA,NA,NA,0,0,TRUE,TRUE,TRUE,NA,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,NA,FALSE,NA,NA,EUCTR2020-000890-25,NA,NA,EudraCT,NA,NA,full_results_preprint,10.1101/2020.03.16.20037135,NA,tdlcb9bf,https://doi.org/10.1101/2020.03.16.20037135,2020-03-20,NA,NA,full_results_journal_article,10.1016/j.ijantimicag.2020.105949,32205204,5o9bbspc,https://www.sciencedirect.com/science/article/pii/S0924857920300996?v=s5; https://doi.org/10.1016/j.ijantimicag.2020.105949; https://www.ncbi.nlm.nih.gov/pubmed/32205204/; https://api.elsevier.com/con,2020-03-20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00596,ChiCTR2000030704,ChiCTR,2020-03-10,2020-02-10,TRUE,The First People's Hospital of Jiangxia District,No Status Given,Phase 4,Interventional,China,Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,50,http://www.chictr.org.cn/showproj.aspx?proj=50778,Suspending,NA,2020-03-10,2020-03-10,0,0,TRUE,TRUE,TRUE,2020-03-10,NA,2020-03-10,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000030704,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.05.20.20107607,NA,1q8972uo,http://medrxiv.org/cgi/content/short/2020.05.20.20107607v1?rss=1,2020-05-26,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00623,ChiCTR2000031630,ChiCTR,2020-04-05,2020-02-17,TRUE,Guangzhou Eighth People's Hospital,Recruiting,Not Applicable,Interventional,China,Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Celecoxib,Celecoxib,60,http://www.chictr.org.cn/showproj.aspx?proj=50474,Recruiting,NA,2020-06-17,2020-06-17,0,0,TRUE,TRUE,TRUE,2020-06-17,NA,2020-06-17,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000031630,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.05.05.20077610,NA,a1gf76bu,http://medrxiv.org/cgi/content/short/2020.05.05.20077610v1?rss=1,2020-05-11,NA,NA,full_results_journal_article,10.3389/fphar.2020.561674,NA,NA,https://www.frontiersin.org/articles/10.3389/fphar.2020.561674/full,2020-11-06,NA,NA,summary_results,NA,NA,NA,https://drive.google.com/file/d/1E88CDMrgichIvQozs4NrCFGcu4t49Reu/view?usp=sharing,NA,NA,registry results as uploaded spreadsheet,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00654,NCT04275414,ClinicalTrials.gov,2020-02-14,2020-02-15,FALSE,Qilu Hospital of Shandong University,Recruiting,Phase 2/Phase 3,Interventional,"China, Italy",Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Drug,Bevacizumab,Bevacizumab,20,https://clinicaltrials.gov/show/NCT04275414,Recruiting,2020-04-01,2020-05-01,2020-04-01,0,0,TRUE,TRUE,TRUE,2020-05-02,2020-04-05,2020-05-02,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04275414,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.1101/2020.07.26.20159756,NA,NA,https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1,2020-07-29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00656,NCT04320238,ClinicalTrials.gov,2020-03-21,2020-01-21,TRUE,Shanghai Jiaotong University,Recruiting,Phase 3,Interventional,China,Experimental Trial of rhIFNa Nasal Drops to Prevent 2019-nCOV in Medical Staff,Drug,Interferon Alpha vs. Interferon Alpha + Thymosin Alpha,Interferon alpha; Thymosin alpha,2944,https://clinicaltrials.gov/show/NCT04320238,Recruiting,2020-05-01,2020-06-01,2020-05-01,0,0,TRUE,TRUE,TRUE,2020-06-01,2020-05-01,2020-06-01,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04320238,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.1101/2020.04.11.20061473,NA,z68tl88x,https://doi.org/10.1101/2020.04.11.20061473,2020-04-17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00732,NCT04261517,ClinicalTrials.gov,2020-02-06,2020-02-06,FALSE,Shanghai Public Health Clinical Center,Not Recruiting,Phase 3,Interventional,China,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,30,https://clinicaltrials.gov/show/NCT04261517,Completed,2020-02-25,2020-02-25,2020-02-25,0,1,TRUE,TRUE,TRUE,2020-02-25,2020-02-25,2020-02-25,NA,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04261517,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.3785/j.issn.1008-9292.2020.03.03,32391667,NA,NA,2020-05-25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00735,NCT04291729,ClinicalTrials.gov,2020-02-27,2020-02-17,TRUE,The Ninth Hospital of Nanchang,Not Recruiting,Phase 4,Interventional,China,Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Drug,Danoprevir + Ritonavir (w/ or w/o Interferon),Danoprevir; Ritonavir; Interferon,11,https://clinicaltrials.gov/show/NCT04291729,Completed,2020-03-19,2020-03-19,2020-03-19,0,0,TRUE,TRUE,TRUE,2020-03-19,2020-03-19,2020-03-19,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04291729,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.1101/2020.03.22.20034041,NA,NA,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1,2020-03-24,NA,NA,full_results_journal_article,10.1097/MD.0000000000023357,33235105,NA,https://journals.lww.com/md-journal/Fulltext/2020/11250/First_clinical_study_using_HCV_protease_inhibitor.53.aspx,2020-11-25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00738,NCT04310228,ClinicalTrials.gov,2020-03-09,2020-03-08,FALSE,Peking University First Hospital,Recruiting,Not Applicable,Interventional,China,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,Drug,Favipiravir + tocilizumab vs. favipiravir vs. tocilizumab,Favipiravir; tocilizumab,150,https://clinicaltrials.gov/show/NCT04310228,Recruiting,2020-05-01,2020-05-01,2020-05-01,0,0,TRUE,TRUE,TRUE,2020-05-01,2020-05-01,2020-05-01,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04310228,ChiCTR2000030894,NA,ClinicalTrials.gov,ChiCTR,NA,full_results_journal_article,10.1016/j.biopha.2020.110825,33378989,NA,https://www.sciencedirect.com/science/article/pii/S0753332220310180?via%3Dihub,2020-09-30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00739,NCT04315480,ClinicalTrials.gov,2020-03-14,2020-03-12,TRUE,Universit Politecnica delle Marche,Not Recruiting,Phase 2,Interventional,Italy,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,Drug,Tocilizumab,Tocilizumab,38,https://clinicaltrials.gov/show/NCT04315480,"Active, not recruiting",2020-04-09,2020-05-01,2020-04-09,0,0,TRUE,TRUE,TRUE,2020-05-01,2020-04-09,2020-05-01,Protocol: https://clinicaltrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04315480,NA,NA,ClinicalTrials.gov,NA,NA,other,10.1101/2020.07.11.20151365,NA,NA,https://www.medrxiv.org/content/10.1101/2020.07.11.20151365v1,2020-07-11,NA,secondary analysis,full_results_preprint,10.21203/rs.3.rs-42117/v1,NA,NA,https://www.researchsquare.com/article/rs-42117/v1,2020-07-22,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00740,NCT04317092,ClinicalTrials.gov,2020-03-19,2020-03-19,TRUE,National Cancer Institute,Recruiting,Phase 2,Interventional,Italy,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Drug,Tocilizumab,Tocilizumab,400,https://clinicaltrials.gov/show/NCT04317092,Recruiting,2020-12-19,2022-12-19,2020-12-19,0,0,TRUE,TRUE,TRUE,2022-12-19,2020-12-19,2022-12-19,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,NCT04317092,EUCTR2020-001110-38,NA,ClinicalTrials.gov,EudraCT,NA,full_results_preprint,10.1101/2020.06.01.20119149,NA,xv0jhsj0,http://medrxiv.org/cgi/content/short/2020.06.01.20119149v1?rss=1,2020-06-05,2020-04-04,NA,full_results_journal_article,10.1186/s12967-020-02573-9,33087150,NA,NA,2020-10-21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00829,ChiCTR2000029434,ChiCTR,2020-02-01,2020-02-01,FALSE,Hebei Yiling Hospital; Renmin Hospital of Wuhan University,Not Recruiting,Phase 4,Interventional,China,"A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,240,http://www.chictr.org.cn/showproj.aspx?proj=48889,Completed,NA,2020-12-01,2020-12-01,0,0,TRUE,TRUE,TRUE,2020-12-01,NA,2020-12-01,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,ChiCTR2000029434,NA,NA,ChiCTR,NA,NA,full_results_journal_article,10.1016/j.phymed.2020.153242,32425361,eb4z3u66,https://api.elsevier.com/content/article/pii/S0944711320300738; https://www.ncbi.nlm.nih.gov/pubmed/32425361/; https://www.sciencedirect.com/science/article/pii/S0944711320300738?v=s5; https://doi.org,2020-05-16,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00850,IRCT20100228003449N28,IRCT,2020-03-19,2020-03-15,TRUE,Tehran University of Medical Sciences,Not Recruiting,Phase 2/Phase 3,Interventional,Iran,Interferon in treatment of COVID-19,Drug,Interferon beta vs. hydroxychloroquine + oseltamivir + Lopinavir/ritonavir,Interferon beta; hydroxychloroquine; oseltamivir; lopinavir/ritonavir,30,http://en.irct.ir/trial/46538,Recruitment complete,NA,NA,NA,0,0,TRUE,TRUE,TRUE,NA,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,NA,FALSE,NA,NA,IRCT20100228003449N28,NA,NA,IRCT,NA,NA,full_results_preprint,10.1101/2020.05.28.20116467,NA,ipvog4m8,http://medrxiv.org/cgi/content/short/2020.05.28.20116467v1?rss=1,2020-05-30,2020-05-03,NA,full_results_journal_article,10.1128/AAC.01061-20,32661006,NA,https://aac.asm.org/content/64/9/e01061-20,2020-08-20,2020-05-03,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00853,IRCT20151227025726N12,IRCT,2020-03-23,2020-03-03,TRUE,Shahid Beheshti University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19),Drug,Interferon beta + hydroxychloroquine + osletamivir + lopinavir/ritonavir,Interferon beta; hydroxychloroquine; oseltamivir; lopinavir/ritonavir,20,http://en.irct.ir/trial/46561,Recruitment complete,NA,NA,NA,0,0,TRUE,TRUE,TRUE,NA,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,NA,FALSE,NA,NA,IRCT20151227025726N12,NA,NA,IRCT,NA,NA,full_results_journal_article,10.1016/j.intimp.2020.106688,32544867,m7rx8tv9,https://www.ncbi.nlm.nih.gov/pubmed/32544867/; https://doi.org/10.1016/j.intimp.2020.106688; https://www.sciencedirect.com/science/article/pii/S1567576920312893?v=s5; https://api.elsevier.com/content/,2020-06-07,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00862,IRCT20190727044343N1,IRCT,2020-04-05,2020-03-16,TRUE,Mazandaran University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,?Effect of febuxostat against coronavirus,Drug,Acetaminophen + Febuxostat vs.  Acetaminophen + Hydroxychloroquine,Febuxostat; Acetaminophen; Hydroxychloroquine,60,http://en.irct.ir/trial/46629,Recruitment complete,NA,2020-04-09,2020-04-09,0,0,TRUE,TRUE,TRUE,2020-04-09,NA,2020-04-09,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,IRCT20190727044343N1,NA,NA,IRCT,NA,NA,full_results_journal_article,10.1111/ijcp.13600,32603531,NA,https://pubmed.ncbi.nlm.nih.gov/32603531/,2020-06-30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00884,JPRN-JapicCTI-205238,JPRN,2020-03-27,2020-03-31,FALSE,"FUJIFILM Toyama Chemical Co., Ltd.",Recruiting,Phase 3,Interventional,Japan,Phase 3 Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia,Drug,Favipiravir,Favipiravir,96,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205238,recruiting,NA,2020-06-30,2020-06-30,0,0,TRUE,TRUE,TRUE,2020-06-30,NA,2020-06-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,JPRN-JapicCTI-205238,NA,NA,JapicCTI,NA,NA,other,NA,NA,NA,https://www.fujifilm.com/jp/en/news/hq/5451#,2020-09-23,NA,"press release published in September, as of today (2020-12-27) I could not identify a full publication",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00894,NCT04257656,ClinicalTrials.gov,2020-01-31,2020-02-06,FALSE,Capital Medical University,Not Recruiting,Phase 3,Interventional,China,A Trial of Remdesivir in Adults With Severe COVID-19,Drug,Remdesivir,Remdesivir,237,https://clinicaltrials.gov/show/NCT04257656,Terminated,2020-03-30,2020-04-10,2020-03-30,0,1,TRUE,TRUE,TRUE,2020-04-10,2020-03-30,2020-04-10,NA,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04257656,NA,NA,ClinicalTrials.gov,NA,NA,interim_results_journal_article,10.1016/S0140-6736(20)31022-9,32423584,bzeqs5oh,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext,2020-04-29,2020-04-10,NA,other,10.1186/s13063-020-04352-9,32448345,NA,https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04352-9,2020-05-24,NA,protocol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri00896,NCT04276688,ClinicalTrials.gov,2020-02-11,2020-02-10,TRUE,University of Hong Kong,Not Recruiting,Phase 2,Interventional,Hong Kong,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Drug,Lopinavir/ritonavir + Ribavirin + Interferon beta,Lopinavir/ritonavir; Ribavirin; Interferon beta,127,https://clinicaltrials.gov/show/NCT04276688,Completed,2020-03-30,2020-03-31,2020-03-30,0,1,TRUE,TRUE,TRUE,2020-03-31,2020-03-30,2020-03-31,NA,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04276688,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1016/S0140-6736(20)31042-4,32401715,8ljnxihr,https://www.sciencedirect.com/science/article/pii/S0140673620310424; https://doi.org/10.1016/s0140-6736(20)31042-4; https://api.elsevier.com/content/article/pii/S0140673620310424; https://www.ncbi.nlm,2020-05-08,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01010,NCT04351620,ClinicalTrials.gov,2020-04-14,2020-04-01,TRUE,University of Chicago,Recruiting,Phase 1,Interventional,United States,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,20,https://clinicaltrials.gov/show/NCT04351620,Recruiting,2020-06-01,2020-06-01,2020-06-01,0,0,TRUE,TRUE,TRUE,2020-06-01,2020-06-01,2020-06-01,Incidental screening. This trial was terminated per the conference abstract.,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04351620,NA,NA,ClinicalTrials.gov,NA,NA,other,NA,NA,NA,https://acrabstracts.org/abstract/phase-i-trial-of-high-dose-hydroxychloroquine-for-the-treatment-of-ambulatory-patients-with-mild-covid-19-a-study-in-the-effects-of-shifting-public-opinion-on-patient,2020-11-09,2020-05-29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01119,NCT04348474,ClinicalTrials.gov,2020-04-13,2020-04-20,FALSE,Azidus Brasil,Not Recruiting,Phase 1,Interventional,Brazil,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,Drug,Hydroxychloroquine + Azithromycin,Hydroxychloroquine; Azithromycin,200,https://clinicaltrials.gov/show/NCT04348474,Suspended,2020-06-30,2020-07-31,2020-06-30,0,0,TRUE,TRUE,TRUE,2020-07-31,2020-06-30,2020-07-31,More context: https://covexit.com/new-brazilian-study-shows-telemedicine-hydroxychloroquine-treatment-reduce-need-for-hospitalization/,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04348474,NA,NA,ClinicalTrials.gov,NA,NA,other,NA,NA,NA,https://static.poder360.com.br/2020/04/2020.04.15-journal-manuscript-final.pdf,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01164,NCT04358614,ClinicalTrials.gov,2020-04-19,2020-03-16,TRUE,Fabrizio Cantini,Not Recruiting,Phase 2/Phase 3,Interventional,Italy,Baricitinib Therapy in COVID-19,Drug,Baricitinib,Baricitinib,12,https://clinicaltrials.gov/show/NCT04358614,Completed,2020-04-05,2020-04-07,2020-04-05,0,0,TRUE,TRUE,TRUE,2020-04-07,2020-04-05,2020-04-07,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04358614,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1016/j.jinf.2020.04.017,32592703,NA,NA,2020-04-23,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01258,ChiCTR2000032456,ChiCTR,2020-04-29,2020-03-01,TRUE,Shanghai Public Health Clinical Center,Not Recruiting,Not Applicable,Interventional,No Country Given,A Randomized Controlled Trial for the Effects of Low-Oxygen Consumption Instruction on the Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19),Prognosis,No Intervention,No Intervention,100,http://www.chictr.org.cn/showproj.aspx?proj=53048,Completed,NA,2020-05-01,2020-05-01,0,0,TRUE,TRUE,TRUE,2020-05-01,NA,2020-05-01,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000032456,NA,NA,ChiCTR,NA,NA,summary_results,NA,NA,NA,http://www.chictr.org.cn/showproj.aspx?proj=53048,2020-05-04,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01275,NCT04273763,ClinicalTrials.gov,2020-02-14,2020-02-16,FALSE,The Second Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Drug,Bromhexine + Umifenovir + Interferon alpha vs. Umifenovir + interferon alpha,Bromhexine; Umifenovir; interferon alpha,18,https://clinicaltrials.gov/show/NCT04273763,"Active, not recruiting",2020-05-10,2020-06-01,2020-05-10,0,0,TRUE,TRUE,TRUE,2020-06-01,2020-05-10,2020-06-01,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04273763,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1111/cts.12881,32881359,NA,https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12881,2020-09-03,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01358,NCT04368377,ClinicalTrials.gov,2020-04-23,2020-04-06,TRUE,University of Milan,Not Recruiting,Phase 2,Interventional,Italy,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Drug,Tirofiban + Clopidogrel + Aspirin + Fondaparinux,Tirofiban; Clopidogrel; Aspirin; Fondaparinux,5,https://clinicaltrials.gov/show/NCT04368377,Completed,2020-04-23,2020-04-23,2020-04-23,0,0,TRUE,TRUE,TRUE,2020-04-23,2020-04-23,2020-04-23,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04368377,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1016/j.phrs.2020.104950,32450344,qx677js6,https://www.sciencedirect.com/science/article/pii/S1043661820312585?v=s5; https://api.elsevier.com/content/article/pii/S1043661820312585; https://www.ncbi.nlm.nih.gov/pubmed/32450344/; https://doi.org,2020-05-23,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01415,EUCTR2020-001934-37-ES,EU Clinical Trials Register,2020-05-08,2020-05-07,TRUE,Instituto de Investigación Marqués de Valdecilla (IDIVAL),Authorised,Phase 4,Interventional,Spain,USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION,Drug,Corticosteroids,Methylprednisolone,200,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001934-37,['Ongoing'],NA,NA,NA,0,0,TRUE,TRUE,TRUE,NA,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,NA,FALSE,NA,NA,EUCTR2020-001934-37,NA,NA,EudraCT,NA,NA,full_results_preprint,10.1101/2020.06.17.20133579,NA,zql4zhyk,http://medrxiv.org/cgi/content/short/2020.06.17.20133579v1?rss=1,2020-06-18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01419,NCT04324489,ClinicalTrials.gov,2020-03-25,2020-03-06,TRUE,Renmin Hospital of Wuhan University,Not Recruiting,Not Applicable,Interventional,China,DAS181 for Severe COVID-19: Compassionate Use,Drug,DAS181,DAS181,4,https://clinicaltrials.gov/show/NCT04324489,Completed,2020-04-16,2020-04-30,2020-04-16,0,0,TRUE,TRUE,TRUE,2020-04-30,2020-04-16,2020-04-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04324489,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1097/CCE.0000000000000263,33134951,NA,https://pubmed.ncbi.nlm.nih.gov/33134951/,2020-10-01,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01444,NCT04371367,ClinicalTrials.gov,2020-04-29,2020-04-27,TRUE,Assistance Publique – Hôpitaux de Marseille,Recruiting,Phase 2,Interventional,France,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )",Drug,Avdoralimab,Avdoralimab,108,https://clinicaltrials.gov/show/NCT04371367,Recruiting,2020-06-27,2020-10-27,2020-06-27,0,0,TRUE,TRUE,TRUE,2021-03-01,2021-03-01,2021-03-01,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04371367,NA,NA,ClinicalTrials.gov,NA,NA,other,NA,NA,NA,https://www.innate-pharma.com/media/all-press-releases/first-patient-dosed-avdoralimab-phase-ii-clinical-trial-covid-19-patients-severe-pneumonia,2020-04-28,NA,Press release that first patient dosed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01483,NCT04280705,ClinicalTrials.gov,2020-02-20,2020-02-21,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),Recruiting,Phase 3,Interventional,"Denmark, United States, Singapore, United Kingdom, Japan, Germany, Mexico, Greece, South Korea, Spain",Adaptive COVID-19 Treatment Trial (ACTT),Drug,Remdesivir,Remdesivir,800,https://clinicaltrials.gov/show/NCT04280705,Recruiting,2023-04-01,2023-04-01,2023-04-01,0,1,TRUE,TRUE,TRUE,2020-05-21,2020-05-21,2020-05-21,Same doi (10.1056/NEJMoa2007764) for both interim and full result. Recorded as both publication types.,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,FALSE,NA,NA,NCT04280705,EUCTR2020-001052-18,JPRN-jRCT2031190264,ClinicalTrials.gov,EudraCT,jRCT,other,NA,NA,NA,https://clinicaltrials.gov/ProvidedDocs/05/NCT04280705/SAP_002.pdf,2020-05-29,NA,Statistical Analysis Plan (SAP) v3,other,NA,NA,NA,https://clinicaltrials.gov/ProvidedDocs/05/NCT04280705/Prot_001.pdf,2020-04-02,NA,Protocol v3,summary_results,NA,NA,NA,https://clinicaltrials.gov/ct2/show/results/NCT04280705,2020-09-25,NA,Registry results updated 2020-12-09.,full_results_journal_article,10.1056/NEJMoa2007764,32445440,NA,https://www.nejm.org/doi/10.1056/NEJMoa2007764,2020-10-08,2020-04-22,NA,interim_results_journal_article,10.1056/NEJMoa2007764,32445440,NA,NA,2020-05-22,NA,NA
tri01485,NCT04326790,ClinicalTrials.gov,2020-03-26,2020-04-03,TRUE,National and Kapodistrian University of Athens,Recruiting,Phase 2,Interventional,Gibraltar,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Drug,Colchicine,Colchicine,180,https://clinicaltrials.gov/show/NCT04326790,Recruiting,2020-08-31,2020-09-30,2020-08-31,0,1,TRUE,TRUE,TRUE,2020-09-30,2020-08-31,2020-09-30,NA,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,NA,NCT04326790,EUCTR2020-001455-40,NA,ClinicalTrials.gov,EudraCT,NA,full_results_journal_article,10.1001/jamanetworkopen.2020.13136,32579195,NA,NA,2020-06-24,NA,NA,other,10.1016/j.hjc.2020.03.002,32251729,NA,https://www.sciencedirect.com/science/article/pii/S1109966620300610?via%3Dihub,2020-04-03,NA,protocol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01625,IRCT20200328046886N1,IRCT,2020-04-12,2020-03-05,TRUE,Mazandaran University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,The effectiveness of Sovodak (sofosbuvir+daclatasvir) in Covid-19 patients,Drug,Daclatasvir/sofosbuvir,Daclatasvir/sofosbuvir,48,http://en.irct.ir/trial/46885,Recruitment complete,NA,2020-05-04,2020-05-04,0,0,TRUE,TRUE,TRUE,2020-05-04,NA,2020-05-04,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,IRCT20200328046886N1,NA,NA,IRCT,NA,NA,full_results_journal_article,10.1093/jac/dkaa332,32812025,NA,https://pubmed.ncbi.nlm.nih.gov/32812025/,2020-08-19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01798,NCT04322396,ClinicalTrials.gov,2020-03-23,2020-04-06,FALSE,Chronic Obstructive Pulmonary Disease Trial Network,Recruiting,Phase 2,Interventional,Denmark,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Drug (Chemoprophylaxis),Hydroxychloroquine + Azithromycin,Hydroxychloroquine; azithromycin,226,https://clinicaltrials.gov/show/NCT04322396,Recruiting,2020-10-31,2021-03-31,2020-10-31,0,1,TRUE,TRUE,TRUE,2021-03-31,2020-10-31,2021-03-31,NA,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,NA,NCT04322396,NA,NA,ClinicalTrials.gov,NA,NA,other,10.1186/s13063-020-04409-9,32522282,NA,https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04409-9,2020-06-10,NA,protocol,other,10.1186/s13063-020-04795-0,33081817,NA,https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04795-0,2020-10-20,NA,statistical analysis plan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01868,NCT04384380,ClinicalTrials.gov,2020-04-07,2020-04-01,TRUE,Taoyuan General Hospital,Recruiting,Phase 4,Interventional,Taiwan,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,45,https://clinicaltrials.gov/show/NCT04384380,Recruiting,2020-06-30,2020-09-30,2020-06-30,0,1,TRUE,TRUE,TRUE,2020-05-31,2020-05-31,2020-05-31,NA,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04384380,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.1101/2020.07.08.20148841,NA,NA,https://www.medrxiv.org/content/10.1101/2020.07.08.20148841v1,2020-07-10,NA,NA,full_results_journal_article,10.1371/journal.pone.0242763,33264337,NA,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242763,2020-12-02,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01880,NCT04328961,ClinicalTrials.gov,2020-03-23,2020-03-31,FALSE,University of Washington,Recruiting,Phase 2/Phase 3,Interventional,United States,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Drug (Chemoprophylaxis),Hydroxychloroquine vs. Vitamin C,Hydroxychloroquine; Vitamin C,2000,https://clinicaltrials.gov/show/NCT04328961,Recruiting,2020-09-30,2020-10-31,2020-09-30,0,1,TRUE,TRUE,TRUE,2020-10-08,2020-09-24,2020-10-08,NA,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,NA,NCT04328961,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.7326/M20-6519,33284679,NA,NA,2020-12-08,NA,NA,other,10.1186/s13063-020-04446-4,32493478,NA,https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04446-4,2020-06-03,NA,protocol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01886,NCT04340050,ClinicalTrials.gov,2020-04-07,2020-04-10,FALSE,University of Chicago,Not Recruiting,Phase 1,Interventional,United States,COVID-19 Convalescent Plasma,ATMP,Plasma,Plasma,10,https://clinicaltrials.gov/show/NCT04340050,"Active, not recruiting",2020-12-31,2021-12-31,2020-12-31,0,0,TRUE,TRUE,TRUE,2021-12-31,2020-12-31,2021-12-31,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,NCT04340050,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.2139/ssrn.3605131,NA,NA,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3605131,2020-06-16,NA,NA,other,10.1101/2020.06.21.20132944,NA,x2t5h5gu,http://medrxiv.org/cgi/content/short/2020.06.21.20132944v1?rss=1,2020-06-23,NA,NA,other,10.1111/joim.13185,NA,NA,NA,2020-10-09,NA,This is the pub of the medrxiv preprint.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri01919,NCT04378712,ClinicalTrials.gov,2020-04-29,2020-01-21,TRUE,Guangzhou Institute of Respiratory Disease,Not Recruiting,Not Applicable,Interventional,China,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),Drug,Hydrogen + Oxygen,Hydrogen; Oxygen,90,https://clinicaltrials.gov/show/NCT04378712,Completed,2020-03-23,2020-03-23,2020-03-23,0,0,TRUE,TRUE,TRUE,2020-03-23,2020-03-23,2020-03-23,"tricky one, it is about an improved gas mix of oxygen/hydrogen to treat COVID ....",TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04378712,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.21037/jtd-2020-057,32642277,NA,http://jtd.amegroups.com/article/view/40994/html,2020-06-15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02014,NCT04313127,ClinicalTrials.gov,2020-03-15,2020-03-16,FALSE,CanSino Biologics Inc.,Not Recruiting,Phase 1,Interventional,China,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,ATMP,Adenovirus vector,Adenovirus vector,108,https://clinicaltrials.gov/show/NCT04313127,"Active, not recruiting",2020-12-30,2022-12-20,2020-12-30,0,1,TRUE,TRUE,TRUE,2022-12-20,2020-12-30,2022-12-20,Incidental screening. Completion date on registry is obviously wrong based on article.,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,NA,NCT04313127,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1016/S0140-6736(20)31208-3,32450106,uj5deryi,https://doi.org/10.1016/s0140-6736(20)31208-3; https://www.sciencedirect.com/science/article/pii/S0140673620312083; https://www.ncbi.nlm.nih.gov/pubmed/32450106/; https://api.elsevier.com/content/arti,2020-05-22,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02067,NCT04391712,ClinicalTrials.gov,2020-05-04,2020-04-30,TRUE,Lowell General Hospital,Recruiting,Phase 2,Interventional,United States,Cold Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Other (device),Cold Laser Therapy,Cold Laser Therapy,20,https://clinicaltrials.gov/show/NCT04391712,Recruiting,2020-05-30,2020-06-30,2020-05-30,0,0,TRUE,TRUE,TRUE,2020-07-16,2020-05-15,2020-07-16,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04391712,NA,NA,ClinicalTrials.gov,NA,NA,other,10.12659/AJCR.926779,32865522,NA,https://www.amjcaserep.com/abstract/index/idArt/926779,2020-08-07,NA,case study,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02143,NCT04393051,ClinicalTrials.gov,2020-05-16,2020-05-20,FALSE,AOU Pisana,Not Recruiting,Phase 2,Interventional,Italy,Baricitinib Compared to Standard Therapy in Patients With COVID-19,Drug,Baricitinib,Baricitinib,126,https://clinicaltrials.gov/show/NCT04393051,Not yet recruiting,2020-06-30,2020-07-30,2020-06-30,0,1,TRUE,TRUE,TRUE,2020-07-30,2020-06-30,2020-07-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04393051,NA,NA,ClinicalTrials.gov,NA,NA,other,NA,NA,NA,https://www.simit.org/formazione/protocolli-covid-19/56-baricivid-19-study-multicentre-randomised-phase-iia-clinical-trial-evaluating-efficacy-and-tolerability-of-baricitinib-as-add-on-treatment-of-pa,2020-04-22,NA,Protocol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02189,NCT04399746,ClinicalTrials.gov,2020-05-19,2020-03-15,TRUE,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,Recruiting,Not Applicable,Interventional,Mexico,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,Drug,Ivermectin + Azithromycin + Cholecalciferol,Ivermectin; Azithromycin; Cholecalciferol,30,https://clinicaltrials.gov/show/NCT04399746,Recruiting,2020-05-20,2020-06-10,2020-05-20,0,0,TRUE,TRUE,TRUE,2020-06-10,2020-05-20,2020-06-10,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04399746,NA,NA,ClinicalTrials.gov,NA,NA,other,NA,NA,NA,https://www.biomedres.info/biomedical-research/effects-of-ivermectinazithromycincholecalciferol-combined-therapy-on-covid19-infected-patients-a-proof-of-concept-study-14435.html,2020-08-15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02198,ChiCTR2000033372,ChiCTR,2020-05-29,2020-03-12,TRUE,Shandong University Qilu Hospital,Not Recruiting,Not Applicable,Interventional,China,Efficacy and safety of leflunomide for Refractory novel coronavirus pneumonia (COVID-19): A non-Randomized Controlled Study,Drug,Leflunomide,Leflunomide,30,http://www.chictr.org.cn/showproj.aspx?proj=54408,Completed,NA,2020-05-17,2020-05-17,0,0,TRUE,TRUE,TRUE,2020-05-17,NA,2020-05-17,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,ChiCTR2000033372,NA,NA,ChiCTR,NA,NA,full_results_preprint,10.1101/2020.05.29.20114223,NA,NA,https://www.medrxiv.org/content/10.1101/2020.05.29.20114223v1.article-info,2020-06-02,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02324,NCT04321421,ClinicalTrials.gov,2020-03-23,2020-03-17,TRUE,Foundation IRCCS San Matteo Hospital,Not Recruiting,Not Applicable,Interventional,Italy,Hyperimmune Plasma for Critical Patients With COVID-19,ATMP,Plasma,Plasma,49,https://clinicaltrials.gov/show/NCT04321421,Completed,2020-04-28,2020-05-07,2020-04-28,0,1,TRUE,TRUE,TRUE,2020-05-07,2020-04-28,2020-05-07,NA,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04321421,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.1101/2020.05.26.20113373,NA,ze4bvjkt,http://medrxiv.org/cgi/content/short/2020.05.26.20113373v1?rss=1,2020-05-29,2020-04-28,NA,other,10.1007/s11739-020-02384-2,32468508,NA,https://link.springer.com/article/10.1007%2Fs11739-020-02384-2,2020-05-28,NA,Protocol,full_results_journal_article,10.3324/haematol.2020.261784,33256382,NA,https://haematologica.org/article/view/9826,2020-07-23,2020-04-28,pre-published date,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02445,NCT04292730,ClinicalTrials.gov,2020-02-28,2020-03-15,TRUE,Gilead Sciences,Not Recruiting,Phase 3,Interventional,"Hong Kong, United States, Netherlands, Singapore, Sweden, France, Germany, Italy, Japan, Switzerland, Taiwan, China, United Kingdom, Iran, South Korea, Spain",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Drug,Remdesivir,Remdesivir,1600,https://clinicaltrials.gov/show/NCT04292730,"Active, not recruiting",2020-06-01,2020-06-01,2020-06-01,0,0,TRUE,TRUE,TRUE,2020-06-26,2020-04-29,2020-06-26,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04292730,EUCTR2020-000842-32,NA,ClinicalTrials.gov,EudraCT,NA,full_results_journal_article,10.1001/jama.2020.16349,32821939,NA,https://pubmed.ncbi.nlm.nih.gov/32821939/#affiliation-1,2020-08-21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02446,NCT04292899,ClinicalTrials.gov,2020-02-28,2020-03-06,TRUE,Gilead Sciences,Not Recruiting,Phase 3,Interventional,"Hong Kong, United States, Netherlands, Singapore, Sweden, France, Germany, Italy, Japan, Switzerland, Taiwan, China, United Kingdom, South Korea, Spain",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Drug,Remdesivir,Remdesivir,6000,https://clinicaltrials.gov/show/NCT04292899,"Active, not recruiting",2020-06-01,2020-06-01,2020-06-01,0,1,TRUE,TRUE,TRUE,2020-06-30,2020-04-09,2020-06-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04292899,EUCTR2020-000841-15,ISRCTN15874265,ClinicalTrials.gov,EudraCT,ISRCTN,full_results_journal_article,10.1056/NEJMoa2015301,32459919,NA,https://www.nejm.org/doi/10.1056/NEJMoa2015301,2020-05-27,NA,NA,summary_results,NA,NA,NA,https://clinicaltrials.gov/ct2/show/results/NCT04292899,2020-12-31,NA,NA,other,10.1056/NEJMoa2015301,32459919,NA,https://www.nejm.org/doi/suppl/10.1056/NEJMoa2015301/suppl_file/nejmoa2015301_protocol.pdf,2020-05-27,NA,protocol (supplement to publication),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02448,NCT04322123,ClinicalTrials.gov,2020-03-24,2020-04-01,FALSE,Hospital do Coração,Not Recruiting,Phase 3,Interventional,Brazil,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),Drug,Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine,Hydroxychloroquine; azithromycin,630,https://clinicaltrials.gov/show/NCT04322123,"Active, not recruiting",2020-08-30,2020-08-30,2020-08-30,0,0,TRUE,NA,NA,NA,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NCT04322123,RBR-9d8z6m,NA,ClinicalTrials.gov,ReBec,NA,full_results_journal_article,10.1056/NEJMoa2019014,32706953,NA,NA,2020-07-23,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02451,NCT04329832,ClinicalTrials.gov,2020-03-30,2020-03-30,FALSE,"Intermountain Health Care, Inc.",Recruiting,Phase 2,Interventional,United States,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,Drug,Hydroxychloroquine vs. Azithromycin,Hydroxychloroquine; azithromycin,300,https://clinicaltrials.gov/show/NCT04329832,Recruiting,2020-12-31,2021-12-31,2020-12-31,0,1,TRUE,TRUE,TRUE,2021-12-31,2020-12-18,2021-12-31,"Trial completion date as of cutoff (2020-06-30) was after cutoff, but found full result journal article on registry so searched for preprint during reconciliation and none found",TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,NA,NCT04329832,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1513/AnnalsATS.202008-940OC,33166179,NA,https://www.atsjournals.org/doi/10.1513/AnnalsATS.202008-940OC,2020-11-09,NA,NA,other,10.1513/AnnalsATS.202004-309SD,32425051,NA,https://www.atsjournals.org/doi/abs/10.1513/AnnalsATS.202004-309SD,2020-08-01,NA,Protocol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02510,NCT04408209,ClinicalTrials.gov,2020-05-25,2020-04-23,TRUE,National and Kapodistrian University of Athens,Recruiting,Not Applicable,Interventional,Greece,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,ATMP,Plasma,Plasma,60,https://clinicaltrials.gov/show/NCT04408209,Recruiting,2020-06-30,2021-09-15,2020-06-30,0,0,TRUE,TRUE,TRUE,2021-09-15,2021-08-30,2021-09-15,Press release here: https://greece.greekreporter.com/2020/08/24/greek-plasma-therapy-trials-for-covid-19-show-promising-results/,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04408209,NA,NA,ClinicalTrials.gov,NA,NA,interim_results_preprint,10.21203/rs.3.rs-64465/v1,NA,NA,https://www.researchsquare.com/article/rs-64465/v1,2020-09-08,NA,"preliminary report, preprint",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02513,NCT04408456,ClinicalTrials.gov,2020-05-24,2020-03-01,TRUE,Postgraduate Institute of Medical Education and Research,Recruiting,Phase 3,Interventional,India,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,200,https://clinicaltrials.gov/show/NCT04408456,Recruiting,2020-06-30,2020-06-30,2020-06-30,0,0,TRUE,TRUE,TRUE,2020-07-31,2020-07-31,2020-07-31,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04408456,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1016/j.ijantimicag.2020.106224,33166694,NA,https://www.sciencedirect.com/science/article/pii/S0924857920304350?via%3Dihub,2020-11-06,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02562,NCT04332081,ClinicalTrials.gov,2020-03-30,2020-04-06,FALSE,NYU Langone Health,Not Recruiting,Not Applicable,Interventional,United States,Hyperbaric Oxygen for COVID-19 Patients,Drug,Oxygen,Oxygen,20,https://clinicaltrials.gov/show/NCT04332081,Terminated,2020-05-29,2020-05-29,2020-05-29,0,0,TRUE,TRUE,TRUE,2020-05-29,2020-05-29,2020-05-29,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04332081,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,NA,32931666,NA,https://pubmed.ncbi.nlm.nih.gov/32931666/,2020-09-09,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02568,NCT04343092,ClinicalTrials.gov,2020-04-05,2020-04-18,FALSE,University of Baghdad,Not Recruiting,Phase 1,Interventional,Iraq,Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,Drug,Ivermectin + hydroxychloroquine vs. hydroxychloroquine,Ivermectin; hydroxychloroquine,100,https://clinicaltrials.gov/show/NCT04343092,Completed,2020-05-31,2020-06-01,2020-05-31,0,0,TRUE,TRUE,TRUE,2020-06-01,2020-05-31,2020-06-01,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04343092,NA,NA,ClinicalTrials.gov,NA,NA,summary_results,NA,NA,NA,https://clinicaltrials.gov/ct2/show/results/NCT04343092,2020-11-04,NA,NA,full_results_preprint,10.1101/2020.07.07.20145979,NA,NA,https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1,2020-07-08,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02674,EUCTR2020-001270-29-GB,EU Clinical Trials Register,2020-03-30,2020-04-02,FALSE,Sanofi,Not Recruiting,Phase 2/Phase 3,Interventional,"Czech Republic, Denmark, Hungary, United Kingdom, France, Germany",Hydroxychloroquine for COVID 19 in moderately to severely ill hospitalized patients,Drug,Hydroxychloroquine,Hydroxychloroquine,350,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001270-29,"['Temporarily Halted', 'Prematurely Ended', 'Temporarily Halted', 'Temporarily Halted', 'Prematurely Ended']",NA,2020-06-25,2020-06-25,0,0,TRUE,TRUE,TRUE,2020-06-25,NA,2020-06-25,prematurely ended,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,EUCTR2020-001270-29,NA,NA,EudraCT,NA,NA,summary_results,NA,NA,NA,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001270-29/results,2020-10-24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02772,IRCT20200128046294N2,IRCT,2020-03-14,2020-03-26,FALSE,Digestive Disease Research Institute,Not Recruiting,Phase 3,Interventional,Iran,Study to Evaluate the Safety and Efficacy of Sofosbuvir/Daclatasvir in Participants with Moderate to Severe Coronavirus Disease (COVID-19),Drug,Sofosbuvir + Daclatasvir,Sofosbuvir; Daclatasvir,70,http://en.irct.ir/trial/46463,Recruitment complete,NA,2020-05-18,2020-05-18,0,0,TRUE,TRUE,TRUE,2020-05-18,NA,2020-05-18,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,IRCT20200128046294N2,NA,NA,IRCT,NA,NA,full_results_journal_article,10.1093/jac/dkaa334,32812039,NA,https://academic.oup.com/jac/article/75/11/3379/5889948,2020-08-19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02845,IRCT20200523047550N1,IRCT,2020-06-06,2020-04-20,TRUE,Tehran University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,Effect of Umifenovir in treatment of covid-19,Drug,Umifenovir + Hydroxychloroquine vs Hydroxychloroquine,Umifenovir; Hydroxychloroquine,50,http://en.irct.ir/trial/48495,Recruitment complete,NA,2020-05-25,2020-05-25,0,0,TRUE,TRUE,TRUE,2020-05-25,NA,2020-05-25,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,IRCT20200523047550N1,NA,NA,IRCT,NA,NA,full_results_preprint,10.21203/rs.3.rs-91430/v1,NA,NA,https://www.researchsquare.com/article/rs-91430/v1,2020-10-19,2020-06-04,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02863,JPRN-UMIN000040341,JPRN,2020-05-09,2020-05-09,FALSE,Takanawa Clinic,Not Recruiting,Not Applicable,Interventional,Japan,Immunological efficacy of Qing Fei Pai Du Tang for COVID-19,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,15,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046023,No longer recruiting,NA,2020-05-16,2020-05-16,0,0,TRUE,TRUE,TRUE,2020-05-16,NA,2020-05-16,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,JPRN-UMIN000040341,NA,NA,UMIN-CTR,NA,NA,full_results_preprint,10.1101/2020.07.13.20146175,NA,NA,https://www.medrxiv.org/content/10.1101/2020.07.13.20146175v1,2020-07-20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02866,JPRN-UMIN000040407,JPRN,2020-05-15,2020-05-15,FALSE,Takanawa Clinic,Not Recruiting,Not Applicable,Interventional,Japan,Immunological efficacy of Jinhua Qinggan Granule for COVID-19,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,15,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046108,No longer recruiting,NA,2020-05-20,2020-05-20,0,0,TRUE,TRUE,TRUE,2020-05-20,NA,2020-05-20,"TRN search string modified to remove ""JPRN-""",TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,JPRN-UMIN000040407,NA,NA,UMIN-CTR,NA,NA,full_results_preprint,10.1101/2020.06.08.20124453,NA,NA,https://www.medrxiv.org/content/10.1101/2020.06.08.20124453v1,2020-06-12,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02914,RPCEC00000313,RPCEC,2020-05-14,2020-03-31,TRUE,"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Not Recruiting,Not Applicable,Interventional,Cuba,CIGB-258 at COVID-19,Drug,CIGB-258,CIGB-258,16,https://rpcec.sld.cu/en/trials/RPCEC00000313-En,Complete,NA,2020-04-30,2020-04-30,0,0,TRUE,TRUE,TRUE,2020-04-30,NA,2020-04-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,RPCEC00000313,NA,NA,RPCEC,NA,NA,other,NA,NA,NA,https://www.preprints.org/manuscript/202009.0240/v1,2020-09-11,NA,NA,full_results_preprint,10.1101/2020.05.27.20110601,NA,NA,https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1,2020-06-02,NA,NA,full_results_journal_article,NA,NA,NA,https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v8-id1119.php,2020-09-17,NA,NA,other,NA,NA,NA,http://revmedmilitar.sld.cu/index.php/mil/article/view/926/625,2020-09-30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02918,RPCEC00000317,RPCEC,2020-05-28,2020-06-01,FALSE,"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Not Recruiting,Phase 1/Phase 2,Interventional,Cuba,ATENEA-Co-300 study,Drug,CIGB-300,CIGB-300,20,https://rpcec.sld.cu/en/trials/RPCEC00000317-En,Pending,NA,2020-06-29,2020-06-29,0,0,TRUE,TRUE,TRUE,2020-06-29,NA,2020-06-29,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,RPCEC00000317,NA,NA,RPCEC,NA,NA,full_results_preprint,10.1101/2020.09.03.20187112,NA,NA,https://www.medrxiv.org/content/10.1101/2020.09.03.20187112v2,2020-09-15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri02934,NCT04316377,ClinicalTrials.gov,2020-03-13,2020-03-25,FALSE,"University Hospital, Akershus",Not Recruiting,Phase 4,Interventional,Norway,Norwegian Coronavirus Disease 2019 Study,Drug,Hydroxychloroquine,Hydroxychloroquine,53,https://clinicaltrials.gov/show/NCT04316377,"Active, not recruiting",2020-05-25,2025-03-03,2020-05-25,0,1,TRUE,TRUE,TRUE,2025-03-03,2020-05-25,2025-03-03,"Because of rapidly decreasing incidence of COVID-19 in Norway, the trial was prematurely stopped by the trial sponsor on May 25, 2020",TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04316377,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1038/s41467-020-19056-6,33082342,NA,https://www.nature.com/articles/s41467-020-19056-6,2020-10-20,NA,NA,full_results_journal_article,10.1038/s41467-020-19056-6,33082342,NA,https://www.nature.com/articles/s41467-020-19056-6,2020-10-20,2020-05-25,NA,full_results_preprint,10.21203/rs.3.rs-44055/v1,NA,NA,https://www.researchsquare.com/article/rs-44055/v1,2020-07-17,NA,NA,other,10.1186/s13063-020-04420-0,32503662,NA,https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04420-0,2020-06-05,NA,protocol,NA,NA,NA,NA,NA,NA,NA,NA
tri03028,NCT04331795,ClinicalTrials.gov,2020-04-01,2020-04-04,FALSE,University of Chicago,Not Recruiting,Phase 2,Interventional,United States,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Drug,Tocilizumab,Tocilizumab,32,https://clinicaltrials.gov/show/NCT04331795,Completed,2020-06-05,2020-06-05,2020-06-05,0,0,TRUE,TRUE,TRUE,2020-06-05,2020-06-05,2020-06-05,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04331795,NA,NA,ClinicalTrials.gov,NA,NA,other,10.1158/1557-3265.COVID-19-S05-02,NA,NA,https://clincancerres.aacrjournals.org/content/26/18_Supplement/S05-02.abstract,2020-09-01,NA,Abstract,full_results_preprint,10.1101/2020.07.20.20157503,NA,NA,https://www.medrxiv.org/content/10.1101/2020.07.20.20157503v1,2020-07-26,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03183,EUCTR2020-001243-15-BE,EU Clinical Trials Register,2020-03-27,2020-03-26,TRUE,UZ Leuven,Not Recruiting,Phase 2,Interventional,Belgium,"Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.",Drug,Itraconazole,Itraconazole,200,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001243-15,['Completed'],NA,2020-06-10,2020-06-10,0,0,TRUE,TRUE,TRUE,2020-06-10,NA,2020-06-10,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,EUCTR2020-001243-15,NA,NA,EudraCT,NA,NA,summary_results,NA,NA,NA,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001243-15/results,2021-01-03,NA,NA,full_results_preprint,10.2139/ssrn.3731461,NA,NA,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3731461,2020-12-10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03202,NCT04346446,ClinicalTrials.gov,2020-04-14,2020-04-20,FALSE,"Institute of Liver and Biliary Sciences, India",Not Recruiting,Phase 2,Interventional,India,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,ATMP,Plasma,Plasma,29,https://clinicaltrials.gov/show/NCT04346446,Completed,2020-05-30,2020-05-30,2020-05-30,0,0,TRUE,TRUE,TRUE,2020-05-30,2020-05-30,2020-05-30,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04346446,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.1101/2020.10.25.20219337,NA,NA,https://www.medrxiv.org/content/10.1101/2020.10.25.20219337v1,2020-10-27,2020-05-30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03275,NCT04288102,ClinicalTrials.gov,2020-02-24,2020-03-05,FALSE,Beijing 302 Hospital,Not Recruiting,Phase 2,Interventional,China,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),100,https://clinicaltrials.gov/show/NCT04288102,"Active, not recruiting",2020-05-12,2020-07-10,2020-05-12,0,0,TRUE,TRUE,TRUE,2020-07-09,2020-05-12,2020-07-09,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04288102,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.1101/2020.10.15.20213553,NA,NA,https://www.medrxiv.org/content/10.1101/2020.10.15.20213553v2,2020-10-21,NA,NA,full_results_preprint,10.2139/ssrn.3680611,32864128,NA,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3680611,2020-10-14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03276,NCT04304053,ClinicalTrials.gov,2020-03-05,2020-03-18,TRUE,Fundació Lluita contra la SIDA,Not Recruiting,Phase 3,Interventional,Spain,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Drug (Chemoprophylaxis),Darunavir + cobicistat + hydroxychloroquine,Darunavir; cobicistat; hydroxychloroquine,2250,https://clinicaltrials.gov/show/NCT04304053,Completed,2020-06-15,2020-06-15,2020-06-15,0,0,TRUE,TRUE,TRUE,2020-06-15,2020-06-15,2020-06-15,The publication date for the SSRN preprint and full-results article are the same,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04304053,EUCTR2020-001031-27,NA,ClinicalTrials.gov,EudraCT,NA,full_results_preprint,10.1101/2020.07.20.20157651,NA,NA,https://europepmc.org/article/PPR/PPR192214,2020-07-26,NA,NA,full_results_journal_article,10.1093/cid/ciaa1009,32674126,NA,NA,2020-07-16,NA,Early Treatment,full_results_preprint,10.2139/ssrn.3615997,NA,NA,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3615997,2020-07-16,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03277,NCT04308668,ClinicalTrials.gov,2020-03-11,2020-03-17,FALSE,University of Minnesota,Not Recruiting,Phase 3,Interventional,"United States, Canada",Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,1309,https://clinicaltrials.gov/show/NCT04308668,Completed,2020-05-20,2020-05-20,2020-05-20,0,1,TRUE,TRUE,TRUE,2020-05-20,2020-05-20,2020-05-20,NA,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04308668,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1056/NEJMoa2016638,32492293,NA,NA,2020-06-03,2020-05-06,NA,full_results_journal_article,10.7326/M20-4207,32673060,NA,https://www.acpjournals.org/doi/10.7326/M20-4207,2020-07-16,2020-06-15,"last patient last date is not last data, so chose later date: ""follow-up concluded on 20 May, and final hospital outcomes were known by 15 June 2020""",other,10.1093/ofid/ofaa500,33204764,NA,NA,2020-10-19,NA,secondary analysis,other,10.1007/s12630-020-01684-7,32383125,NA,https://link.springer.com/article/10.1007/s12630-020-01684-7,2020-05-07,NA,protocol,NA,NA,NA,NA,NA,NA,NA,NA
tri03303,NCT04343729,ClinicalTrials.gov,2020-04-09,2020-04-18,FALSE,Fundação de Medicina Tropical Dr. Heitor Vieira Dourado,Not Recruiting,Phase 2,Interventional,Brazil,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,Drug,Corticosteroids,Methylprednisolone,425,https://clinicaltrials.gov/show/NCT04343729,"Active, not recruiting",2020-06-16,2020-09-01,2020-06-16,0,0,TRUE,TRUE,TRUE,2020-09-01,2020-06-16,2020-09-01,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04343729,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1093/cid/ciaa1177,32785710,NA,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1177/5891816,2020-08-12,2020-06-16,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03309,NCT04346355,ClinicalTrials.gov,2020-04-12,2020-03-31,TRUE,Azienda Unita Sanitaria Locale Reggio Emilia,Not Recruiting,Phase 2,Interventional,Italy,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Drug,Tocilizumab,Tocilizumab,126,https://clinicaltrials.gov/show/NCT04346355,Terminated,2020-06-06,2020-06-06,2020-06-06,0,0,TRUE,TRUE,TRUE,2020-06-06,2020-06-06,2020-06-06,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04346355,EUCTR2020-001386-37,NA,ClinicalTrials.gov,EudraCT,NA,full_results_journal_article,10.1001/jamainternmed.2020.6615,33080005,NA,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772186,2020-10-20,2020-06-11,"On June 11, 2020, the trial Scientific Committee decided to interrupt the study for futility with an enrollment of 126 patients.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03312,NCT04349241,ClinicalTrials.gov,2020-04-13,2020-04-18,FALSE,Ain Shams University,Not Recruiting,Phase 3,Interventional,Egypt,Efficacy and Safety of Favipiravir in Management of COVID-19,Drug,Favipiravir,Favipiravir,100,https://clinicaltrials.gov/show/NCT04349241,Completed,2020-06-01,2020-06-20,2020-06-01,0,0,TRUE,TRUE,TRUE,2020-06-20,2020-06-01,2020-06-20,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04349241,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.21203/rs.3.rs-83677/v1,NA,NA,https://www.researchsquare.com/article/rs-83677/v1,2020-09-29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03326,NCT04356534,ClinicalTrials.gov,2020-04-15,2020-04-19,FALSE,Royal College of Surgeons in Ireland - Medical University of Bahrain,Recruiting,Not Applicable,Interventional,Bahrain,Convalescent Plasma Trial in COVID -19 Patients,ATMP,Plasma,Plasma,40,https://clinicaltrials.gov/show/NCT04356534,Recruiting,2020-06-30,2020-06-30,2020-06-30,0,0,TRUE,TRUE,TRUE,2020-07-09,2020-06-15,2020-07-09,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04356534,NA,NA,ClinicalTrials.gov,NA,NA,full_results_preprint,10.1101/2020.11.02.20224303,NA,NA,https://www.medrxiv.org/content/10.1101/2020.11.02.20224303v1,2020-11-04,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03327,NCT04356937,ClinicalTrials.gov,2020-04-19,2020-04-20,FALSE,Massachusetts General Hospital,Recruiting,Phase 3,Interventional,United States,Efficacy of Tocilizumab on Patients With COVID-19,Drug,Tocilizumab,Tocilizumab,278,https://clinicaltrials.gov/show/NCT04356937,Recruiting,2020-06-30,2020-08-30,2020-06-30,0,0,TRUE,TRUE,TRUE,2020-08-27,2020-07-13,2020-08-27,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04356937,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1056/NEJMoa2028836,33085857,NA,https://www.nejm.org/doi/10.1056/NEJMoa2028836,2020-10-21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03358,NCT04369742,ClinicalTrials.gov,2020-04-25,2020-04-15,TRUE,NYU Langone Health,Not Recruiting,Phase 2,Interventional,United States,Treating COVID-19 With Hydroxychloroquine (TEACH),Drug,Hydroxychloroquine,Hydroxychloroquine,626,https://clinicaltrials.gov/show/NCT04369742,Suspended,2020-06-01,2020-06-01,2020-06-01,0,0,TRUE,TRUE,TRUE,2021-06-01,2021-06-01,2021-06-01,Suspended which does not mean withdrawn prior to enrolling any patients (so should still report),TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04369742,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,10.1093/ofid/ofaa446,33134417,NA,https://academic.oup.com/ofid/article/7/10/ofaa446/5910201,2020-09-23,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03436,NCT04410159,ClinicalTrials.gov,2020-05-27,2020-06-22,FALSE,Universiti Sains Islam Malaysia,Recruiting,Phase 2,Interventional,Malaysia,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Drug,Povidone Iodine vs. Essential Oil,Povidone Iodine; Essential Oil,20,https://clinicaltrials.gov/show/NCT04410159,Recruiting,2020-07-15,2020-08-15,2020-07-15,0,1,TRUE,TRUE,TRUE,2020-07-06,2020-06-29,2020-07-06,"Changed completion date to be before cut-off, after the cut-off.",TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,NA,NCT04410159,NA,NA,ClinicalTrials.gov,NA,NA,summary_results,NA,NA,NA,https://clinicaltrials.gov/ct2/show/results/NCT04410159,2020-07-21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03458,NCT04422561,ClinicalTrials.gov,2020-06-06,2020-05-31,TRUE,Zagazig University,Recruiting,Phase 2/Phase 3,Interventional,Egypt,Prophylactic Ivermectin in COVID-19 Contacts,Drug (Chemoprophylaxis),Ivermectin,Ivermectin,100,https://clinicaltrials.gov/show/NCT04422561,Recruiting,2020-06-01,2020-07-01,2020-06-01,0,0,TRUE,TRUE,TRUE,2020-07-27,2020-07-14,2020-07-27,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,FALSE,TRUE,NA,NA,NCT04422561,NA,NA,ClinicalTrials.gov,NA,NA,summary_results,NA,NA,NA,https://clinicaltrials.gov/ct2/show/results/NCT04422561,2020-08-27,NA,NA,other,NA,NA,NA,https://clinicaltrials.gov/ProvidedDocs/61/NCT04422561/Prot_SAP_000.pdf,2020-05-31,NA,protocol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03558,NCT04441424,ClinicalTrials.gov,2020-06-12,2020-04-03,TRUE,Alkarkh Health Directorate-Baghdad,Not Recruiting,Not Applicable,Interventional,Iraq,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,ATMP (+ Drug),Plasma + Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine + Azithromycin,Plasma; Hydroxychloroquine; Azithromycin,49,https://clinicaltrials.gov/show/NCT04441424,Completed,2020-06-01,2020-06-01,2020-06-01,0,0,TRUE,TRUE,TRUE,2020-06-01,2020-06-01,2020-06-01,NA,TRUE,TRUE,TRUE,TRUE,TRUE,FALSE,TRUE,TRUE,TRUE,TRUE,NA,NA,NCT04441424,NA,NA,ClinicalTrials.gov,NA,NA,full_results_journal_article,NA,32920571,NA,https://europepmc.org/article/med/32920571,2020-09-01,NA,no doi from journal,full_results_preprint,10.1101/2020.06.24.20121905,NA,NA,https://www.medrxiv.org/content/10.1101/2020.06.24.20121905v1?versioned=true,2020-06-29,NA,NA,other,NA,NA,NA,https://clinicaltrials.gov/ProvidedDocs/24/NCT04441424/Prot_SAP_000.pdf,2020-06-01,NA,protocol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
tri03746,NCT04381936,ClinicalTrials.gov,2020-05-07,2020-03-19,TRUE,University of Oxford,Recruiting,Phase 2/Phase 3,Interventional,United Kingdom,Randomized Evaluation of COVID-19 Therapy,Drug,Lopinavir/ritonavir vs. corticosteroids vs. hydroxychloroquine vs. azithromycin vs. tocilizumab,Lopinavir/ritonavir; dexamethasone; hydrocortisone;  hydroxychloroquine; azithromycin; tocilizumab,12000,https://clinicaltrials.gov/ct2/show/NCT04381936,Recruiting,2020-12-01,2021-06-01,2020-12-01,0,0,TRUE,TRUE,TRUE,2031-12-01,2021-12-01,2031-12-01,NA,TRUE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,NA,NA,NCT04381936,EUCTR2020-001113-21,ISRCTN50189673,ClinicalTrials.gov,EudraCT,ISRCTN,interim_results_preprint,10.1101/2020.06.22.20137273,NA,ocguwlam,http://medrxiv.org/cgi/content/short/2020.06.22.20137273v1?rss=1,2020-06-22,NA,NA,interim_result,10.1056/NEJMoa2021436,32678530,NA,https://www.nejm.org/doi/10.1056/NEJMoa2021436,2020-07-17,NA,NA,interim_results_journal_article,10.1016/S0140-6736(20)32013-4,33031764,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext,2020-10-05,NA,NA,full_results_journal_article,10.1056/NEJMoa2022926,33031652,NA,https://www.nejm.org/doi/10.1056/NEJMoa2022926,2020-11-19,NA,NA,interim_results_preprint,10.1101/2020.12.10.20245944,NA,NA,NA,2020-12-14,NA,NA
